Background: German university hospitals have started to establish molecular tumor boards in order to enable physicians to make molecular-guided decisions.
Objective: Our aim was to describe the organizational structure and procedures which are currently supporting the molecular tumor boards of five German university hospitals.
Methods: We conducted semi-structured interviews with experts of five university hospitals between December 2016 and February 2017.
Results: We observed heterogeneity in both the organization of genetic testing and the management of the molecular tumor boards among the five hospitals. They used free-text documents in most of their support procedures rather than machine-readable documents.
Conclusion: There are three potentialities to support the process from genetic testing to reporting within the molecular tumor boards: (i) standardized pipeline to integrate automated variant calling and annotation; (ii) tools supporting the experts in creating their reports and presentations and (iii) implementing pharmacogenomic CDSS into clinical routine.
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
Tel.: +1 703 830 6300
Fax: +1 703 830 2300 firstname.lastname@example.org
(Corporate matters and books only) IOS Press c/o Accucoms US, Inc.
For North America Sales and Customer Service
West Point Commons
Lansdale PA 19446
Tel.: +1 866 855 8967
Fax: +1 215 660 5042 email@example.com